- Title
- PS1 Phase 3 KEYNOTE-042 Study: Pembrolizumab vs Platinum-Based Chemotherapy as 1l Therapy for Advanced NSCLC with a PD-L1 TPS ≥1
- Creators
- G Lopes - Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL/USY Wu - Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou/CNI Kudaba - Riga East Clinical University - Latvian Oncology Center, Riga/LVD Kowalski - The Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warszawa/PLB Cho - Yonsei Cancer Center, Seoul/KPH Turna - Istanbul University Cerrahpasa Medical Faculty, Istanbul/TRG De Castro - Instituto do Câncer do Estado de São Paulo, São Paulo/BRV Srimuninnimit - Siriraj Hospital, Mahidol University, Bangkok/THK Laktionov - NN Blokhin Russian Cancer Research Center, Moscow/RUI Bondarenko - Dnipropetrovsk Medical Academy, Dnipropetrovsk/UAK Kubota - Nippon Medical School Hospital, Tokyo/JPG Lubiniecki - Merck & Co., Inc., Kenilworth, NJ/USJ Zhang - Merck & Co., Inc., Kenilworth, NJ/USD Kush - Merck & Co., Inc., Kenilworth, NJ/UST Mok - Chinese University of Hong Kong, Shatin/CN
- Publication Details
- Journal of thoracic oncology, Vol.13(9), pp.S152-S152
- Publisher
- Elsevier Inc
- Academic Unit
- Miller School of Medicine; UMMG Department of Pathology; UMMG Dept of Medicine - Hematology/Oncology
- Language
- English
- Resource Type
- Journal article
- Record Identifier
- 991031600261702976
Journal article
PS1 Phase 3 KEYNOTE-042 Study: Pembrolizumab vs Platinum-Based Chemotherapy as 1l Therapy for Advanced NSCLC with a PD-L1 TPS ≥1
Journal of thoracic oncology, Vol.13(9), pp.S152-S152
2018-09
Metrics
12 Record Views
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites